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Abstract 
 
Little or poor quality sleep is often reported in patients suffering from acute or 
chronic pain.  Conversely, sleep loss has been known to elevate pain perception; thus a 
potential bi-direction relationship exists between sleep deprivation and pain. The effect of 
sleep deprivation on the thermal pain intensity has yet to be determined, furthermore, sex 
differences in pain have not been examined following sleep deprivation.  There is also a 
higher prevalence of insomnia in women, and reports indicate that sleep quality is 
diminished and pain sensitivity may be greater during high hormone phases of the 
menstrual cycle.  In Study 1 we examined the effects of 24-hour total sleep deprivation 
(TSD) on pain intensity during a 2-minute cold pressor test (CPT).  We hypothesized that 
TSD would augment thermal pain intensity during CPT and women would demonstrate 
an elevated response compare to men.  In Study 2 we investigated the effects of 
menstrual phase on pain intensity during CPT following TSD.  We hypothesized that pain 
intensity would be augmented during the mid-luteal (ML) phase of the menstrual cycle.  
In Study 1, pain intensity was recorded during CPT in 14 men and 13 women after 
normal sleep (NS) and TSD.  Pain intensity responses during CPT were elevated in both 
conditions; however, pain intensity was augmented (~Δ1.2 a.u.) following TSD.  When 
analyzed for sex differences, pain intensity was not different between men and women in 
either condition.  In Study 2, pain intensity was recorded during CPT in 10 female 
subjects during the early follicular (EF) and ML phases of the menstrual cycle after TSD.  
Estradiol and progesterone levels were elevated during the ML phase, however, pain 
intensity was not different between the two phases. We conclude that TSD significantly 
augments pain intensity during CPT, but this response is not sex dependent. We further 
demonstrate that the collective effect of TSD and elevated gonadal hormone 
concentrations do not result in a differential pain response during the EF and ML phases 
of the menstrual cycle.  Collectively, sleep loss augments pain intensity ratings in men 
and women and may contribute to sleep loss in painful conditions.   
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Chapter 1 Literature Review 
1.1 Introduction to Pain 
 
Epidemiological studies indicate that approximately one quarter of United States 
(US) residents suffer from some type of pain (Krueger & Stone, 2008; Toblin et al., 
2011).  A recent study examining the economic cost of pain in terms of health care and 
lost productivity in the US estimated the total cost of pain was somewhere between $560 
and $635 billion when referenced to the year 2010 (Gaskin & Richard, 2012). Therefore, 
understanding the processes involved in pain sensation, and developing new strategies for 
the management of pain are paramount for society.  The International Association for the 
Study of Pain describes pain as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such damage” 
(Merskey, 1991).  This chapter will examine the theories of pain along with an 
introduction to the anatomy and physiology involved in the sensation of pain.  
1.1.1 Pain Theory 
 
Human understanding of pain and the mechanisms that bring about a painful 
response has varied greatly since the times of the ancient Greek civilizations. Beginning 
around the end of the 19th century researchers began to focus their efforts on identifying 
the mechanisms contributing to a painful response. Pain theory has been widely debated 
over the years, and has resulted in three main competing theories. 
The specific theory of pain was the first theory to gain almost universal favor 
among scientists, particularly physiologists.  The specific theory of pain is very clear in a 
physiological sense in that free nerve endings are the receptors of pain.  The roots of the 
specific theory can be traced back to Muller who first proposed a special class of nerves 
for the sense of feeling (Muller, 1841; Dallenbach, 1939). Von Frey performed 
pioneering studies in pain sensitivity utilizing punctate stimuli known today as von Frey 
hairs.  Through the use of varying levels of stimuli, Von Frey was able to determine the 
existence of four types of sensory spots on the skin of humans including warmth, cold, 
pressure and pain (von Frey, 1894, 1895, 1896; Dallenbach, 1939).   The existences of 
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pain “spots” lead von Frey to champion the specific theory of pain (Dallenbach, 1939). In 
1906 Sherrington noted that the sensation of pain often involved tissue damage or injury 
and described “noxious stimuli” as any stimulus capable of causing tissue damage or the 
perception of tissue damage. He also described  “nociceptors” as afferents responsible for 
carrying pain signals (Sherrington, 1947). The specific theory suggests a direct path to 
the brain and once a stimulus is detected by a receptor, the signals are transmitted to the 
spinal cord via afferent A-Delta and C fibers and then, directly transmitted to the brain 
(Erlanger & Gasser, 1924; Bishop et al., 1933).  While the specific theory of pain is quite 
simple in a physiological sense, it fails to account for the psychological aspects of pain 
leaving room for competing theories.    
The specific theory of pain was readily accepted by physiologists, but the 
psychologists tended to disagree because the specific theory failed to account for the 
psychological aspects of pain (Kulpe, 1905; Dallenbach, 1939; Melzack & Wall, 1965).  
Goldscheider articulated a theory that indicated that pain sensation is brought about by 
intense stimulus on non-specific sensory receptors (Goldscheider, 1894; Dallenbach, 
1939).   Essentially any stimulus such as cold, heat, pressure, light, sound, or smells, 
given in a large quantity, can cause pain.  An extension of this theory was later proposed 
by Nafe who believe that patterns of stimulation in afferent nerves were responsible for 
pain (Kenshalo & Nafe, 1962).   Weddell and Sinclair further supported the view that 
pain is generated from spatial and temporal summation of impulses arising from painful 
stimuli on non-specific receptors (Sinclair, 1955; Weddell, 1955; Melzack & Wall, 
1965).  The major shortcoming of the pattern theory is that evidence indicates that there 
are multiple forms of specific receptors that encode pain. 
In 1962 Melzack and Wall reviewed the theories of pain transmission and 
articulated the shortcomings of the specific and pattern theories of pain (Melzack & Wall, 
1962).  They proposed the “Gate Control Theory of Pain” to account for the 
shortcomings of both specific and pattern theory (Melzack & Wall, 1965).  The gate 
theory allows for descending control of painful stimuli and recognizes both physiological 
and psychological aspects of pain.   
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The gate theory proposes that pain signaling arises from many different sizes of 
fibers, however, not all signals are transmitted to the brain.  Briefly, the substantia 
gelatinosa, located in the dorsal horn, acts as the pre-synaptic gate modulating the activity 
of both small and large fiber afferents.  The input then is projected to the first central 
transmission or T cells and further to the brain. The spinal cord constantly received input 
from small afferent fibers even without specific stimulation.  Most large myelinated 
fibers are silent without stimulation.  When a stimulus is applied, the large myelinated 
fibers are activated and transmit stimuli that open the gate for a short period of time 
allowing for pain transmission to supraspinal centers.  However, the balance of activity 
between the large and small afferent fibers determines the opening of the gate and 
sustained opening relies upon the activation of small fibers (Melzack & Wall, 1965).  An 
example would be putting a flame to your hand.  Initially the large myelinated fibers 
would fire, opening the gate, and transmitting pain.  However, the sustained pain feeling 
after removal of the flame would be from small myelinated and unmelinated fiber 
activation in response to tissue damage, which holds the gate open and allow for signal 
transmission.  
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Table 1.1. Summary of the three prominent theories of pain. 
 
 
Specific 
Theory 
• Specific receptors for pain including mechanical, 
thermal, and chemoreceptors 
• Direct afferent path to the brain 
 
 
Pattern 
Theory 
• Non-specific receptors 
• Any stimulus, given in a large enough quantity, 
will cause pain 
• Spatial and temporal summation of afferent nerve 
activity results in pain 
 
 
 
 
Gate 
Theory 
• Combination of Specific and Pattern Theories 
• Pre-synaptic gate in the spinal cord modulates 
afferent pain signals 
• Large myelinated fiber activity initially opens the 
gate in response to a large stimulus allowing 
transmission of afferent pain sensation 
• Small unmyelinated fiber activity in response to 
tissue damage continually holds the gate open 
once the stimulus is removed resulting in sustained 
pain sensation 
 
1.1.2 Anatomy of Pain 
 
Prior to the 18th century little evidence was available regarding the pathways of 
the nervous system and their ability to sense pain.  Charles Bell proposed that the dorsal 
and ventral roots in the spinal cord have different functions, and that the ventral root was 
responsible for motor activity (Bell, 1811; Dallenbach, 1939).  The sensory aspect of the 
dorsal root was demonstrated by Francois Magendie several years later (Magendie, 1822; 
Dallenbach, 1939).  Schiff was the first to distinguish the sense of touch and pain from 
each other through studies examining spinal cord lesions.  He discovered when the gray 
matter of the spinal cord was severed, pain would not be felt in areas below the incision, 
but touch remained.  In contrast, when the white matter was severed instead of the gray 
matter, the sense of touch was lost while pain sensation remained intact (Schiff, 1859; 
Perl, 2011). Schiff was able to conclude that touch and pain involved different pathways 
within the spinal cord and that pain and temperature sensation crossed the spinal cord to 
the contralateral side. Following Schiff’s conclusions about crossing pathways within the 
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spinal tract, several scientists supported his data through observations in animals (Brown-
Sequard, 1868; Perl, 2011) and humans (Gowers, 1877).  
Gasser and Erlanger were the first to examine action potentials with the cathode 
ray oscilloscope (Erlanger & Gasser, 1922). New research in the electrical properties of 
nerves allowed for the identification of the fibers responsible for afferent transmission of 
pain. The visualization of the compound action potential in multifibre nerves 
demonstrated specific deflections that were attributed to single fibers within the bundle.  
The A deflection represents the fastest fibers and is attributed to large myelinated fibers 
(Erlanger & Gasser, 1924).  The C deflection represents the slowest fibers and is 
attributed to small unmyelinated fibers (Erlanger & Gasser, 1924; Bishop et al., 1933). 
Nociceptors are responsible for sensing painful stimuli and communicating that 
stimulus to spinal and supraspinal centers for interpretation. One of the first dedicated 
nociceptors to be discovered were thin-myelinated nerves that required high threshold 
mechanical stimulation and exhibit an A deflection on the compound action potential 
(Burgess & Perl, 1967; Perl, 1968).  These fibers have been shown to project to lamina I 
and laminae V and VI in the ipisilateral dorsal horn (Light & Perl, 1979). Once the first 
true nociceptor was discovered, research in the area intensified.  Studies identified and 
demonstrated that nociceptors have a specific response to noxious stimuli including 
mechanical, heat, pressure, cold and acid (Bessou & Perl, 1969; Kumazawa & Perl, 1977; 
Lynn & Carpenter, 1982). 
Most nociceptors are polymodal in that they respond to more than one type of 
stimuli.  There are two distinct types of nociceptors including myelinated A-delta fibers, 
and unmylinated C fibers (Perl, 2011). A-Delta fibers have a medium diameter and are 
responsible for the fast pain response and are further subdivided into two groups.  Type I 
are known as high threshold mechanical receptors and are involved in sensing 
mechanical, chemical, and very high threshold heat stimuli (Basbaum et al., 2009).  Type 
II A fibers have a high mechanical threshold, but a low heat threshold compared to type I 
fibers.  Unmelinated C fibers carry the “slow” pain or secondary response (Basbaum et 
al., 2009). The most common C fibers are mechanical/heat receptors labeled CMH. Other 
populations are heat sensitive, mechanical insensitive nociceptors labeled silent 
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nociceptors that also respond to chemical stimuli such as capsaicin and histamine 
(Schmidt et al., 1995). C fiber nociceptors also respond to cold stimuli (Bessou & Perl, 
1969).  Nociceptors that respond to cold stimuli below 10 °C are different from cold 
thermoreceptors that demonstrate activity between 10 and 40 °C.  Cold thermoreceptors 
are responsible for maintaining proper skin temperature and allow for thermal sensation 
(Kenshalo & Duclaux, 1977).  Medium diameter myelinated A fibers and unmyelinated C 
fibers transmit afferent information from cold thermoreceptors (Hensel et al., 1974).   
Sensory input enters the spinal cord through the dorsal root.  The spinal cord has 3 
distinct areas.  The posterior horn is composed of laminae I-VI, the lateral horn consists 
only of Lamina VII, and the anterior horn is comprised of laminae VIII-IX.  A-delta 
afferents project to lamina I and V, whereas C fibers nociceptors project primarily to 
lamina I (Perl, 2011). Nociceptor afferent nerves enter the spinal cord through the dorsal 
root.  They synapse with secondary afferent nerves and excitatory signals from the 
primary nociceptor afferents causes action potentials in the secondary afferents, which 
carry the pain signal to the brain through the white matter of the spinal cord.  The 
spinothalmic tract is involved in carrying pain signals to the thalamus (Perl, 2011), while 
the spinoreticulothalmic tract terminates in the brainstem (Basbaum et al., 2009).  Pain 
signals from the thalamus and brainstem are sent to higher brain structures including the 
somatosensory cortex, anterior cingulate gyrus and insular cortex among others since it is 
important to note that there is no one center for pain processing in the brain (Apkarian et 
al., 2005).           
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Figure 1.1. Summary of spinal and supraspinal anatomy of pain.  Afferent nerve activity 
enters the spinal cord in the dorsal horn and is transmitted to the thalamus through the 
spinothalmic tract.  Adapted from Basbaum et al., (2009) 
 
 
Thalamus 
Anterior Cingulate Cortex 
Insula 
Pre-Frontal Cortex 
Somatosensory Cortex 
Spinal Reflexes 
Nociceptor 
Afferents 
Spinothalmic 
Tract 
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1.1.3 Sex Differences in the Perception of Pain 
 
Epidemiological studies suggest that women report more chronic pain than men 
(Crook et al., 1984; Reisbord & Greenland, 1985; Unruh, 1996; Fillingim et al., 2009).  
Laboratory-induced pain also demonstrates sex differences, but the results vary based on 
the experimental approach.  Studies utilizing mechanical stimuli consistently demonstrate 
that women have an enhanced pain sensitivity compared to men (Buchanan & Midgley, 
1987; Brennum et al., 1989; Jensen et al., 1992). Pain induced by electric stimulation has 
also demonstrated sex differences (Notermans & Tophoff, 1967; Robin et al., 1987; 
Rollman & Harris, 1987), although several studies have reported no difference (Neri & 
Agazzani, 1984; Ayesh et al., 2007). A substantial number of studies support the 
conclusion that women have a greater sensitivity to heat pain compared to men.  In a 
review of the literature, Fillingim et al. reported that 12 of 17 studies examining heat pain 
threshold and 15 of 16 studies examining heat pain tolerance demonstrated sex 
differences with women reporting more sensitivity to heat pain (Fillingim et al., 2009).  
Cold pain has also demonstrated sex differences and Fillingim et al. noted that 6 of 9 
studies for pain threshold, 14 of 15 studies for pain tolerance, and 13 of 16 studies for 
pain intensity demonstrated sex differences with women reporting higher pain than men 
(Fillingim et al., 2009).  Although experimental pain may be induced by any number of 
paradigms, evidence consistently suggests that women have a higher sensitivity to pain 
than men.   
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Table 1.2. Summary of pain measurements. 
 
Measurement Definition Description 
Pain Threshold 1st sensation of pain 
Level of mechanical or 
thermal stimuli required to 
induce pain.   
Pain Tolerance 
Point where pain 
stimulus become 
unbearable 
Measured during a sustained 
protocol such as the cold 
pressor test or ischemia 
protocol.  Measure of 
tolerance will occur when 
subjects stops the test. 
Pain Intensity 
Level of pain rated 
on a visual analog 
scale 
Measured during a sustained 
protocol such as the cold 
pressor test or ischemia 
protocol.  Subjects rate their 
level of pain at specific time 
points. 
 
1.2 Sleep  
 
Modern human sleep research began with the first study examining brain activity 
with an electroencephalogram (EEG) during sleep.  Loomis et al described varying 
activity in the EEG during sleep in humans and abolished the thought that sleep was one 
homogenous experience within the brain.  Included in their analysis was a description of 
five different types of EEG stages as sleep progressed through the night (Loomis et al., 
1937).  This publication was the first to separate the different stages of sleep based on 
EEG.  Aserinsky & Kleitman (1953) were the first to report the existence of rapid eye 
movements (REM) during particular periods of sleep.  REM sleep periods occurred 
periodically throughout the night, with subsequent periods lasting a shorter time than 
previous.  They also reported that respiratory rate and heart rate increased during REM 
sleep, and further concluded that dreaming occurred during the periods of REM sleep 
(Aserinsky & Kleitman, 1953). Dement and Kleitman expanded the early work on REM 
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sleep by observing EEG during REM stages and reporting fast frequency, low voltage 
EEG activity during REM periods. They also reported that NonREM and REM sleep 
alternate throughout a given session of sleep, and suggested new sleep stages that clearly 
separated REM and NonREM sleep (Dement & Kleitman, 1957).  In 1968 Rechtschaffen 
and Kales proposed a comprehensive scoring system to differentiate the stages of sleep 
based on polysomnography recordings (Rechtschaffen & Kales, 1968).  
Polysomnography recordings during sleep include EEG, electrooculogram (EOG), and 
electromyogram (EMG), and are scored based on 30-second epochs of data. 
1.2.1 Sleep Stages (Rechtschaffen and Kales) 
 
Wake stage displays mixed frequency, low voltage activity in the EEG in the 
range of 2-7 Hz.  Also, alpha activity of 8-13 Hz occurs greater than 50% of the 
recording.  As expected with wakeful movement, there is usually elevated activity 
recorded via EMG (Rechtschaffen & Kales, 1968). 
Stage 1 sleep is a transition state between wakefulness and other stages of sleep 
typically lasting between 1 and 7 minutes.  It also occurs following slight arousals or 
body movements during sleep.  The EEG in Stage 1 sleep displays a mixed frequency of 
low voltage activity, but alpha activity occurs less than 50% of the recording.  There are 
also slow eye movements and less EMG activity than when the patient is awake 
(Rechtschaffen & Kales, 1968). 
Stage 2 sleep is best characterized by the observance of sleep spindles and K 
complexes on the EEG with high frequency, medium voltage waves.  Sleep spindles are 
short bursts, lasting about a half second, with a frequency of 12-14 Hz.  K complexes are 
large waves with a sharp negative and positive peaks lasting not longer than half a second 
(Rechtschaffen & Kales, 1968).   
Stage 3 sleep occurs when 20-50% of the EEG displays waves lower than 2 Hz 
and amplitude greater than 75 microvolts.  Occasionally sleep spindles and K complexes 
are noted in stage 3 sleep (Rechtschaffen & Kales, 1968). 
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Stage 4 sleep is scored when EEG waves occur at a frequency less than 2 Hz with 
amplitudes greater than 75 microvolts are noted more in more than 50% of the scoring 
epoch.  The combination of stage 3 and 4 sleep is collectively termed slow wave sleep 
(SWS) (Rechtschaffen & Kales, 1968). 
REM sleep displays mixed frequency, low voltage EEG activity similar to the 
alpha activity in stage 1 sleep.  There is also specific wave activity termed “saw tooth” on 
the EEG that are only noted in REM sleep.  Sleep spindles and K complexes are not 
noted during REM sleep and there is very low EMG activity (Rechtschaffen & Kales, 
1968). 
1.2.2 Sleep Stages (AASM) 
 
In 2007 the American Academy of Sleep Medicine sought to re-examine the 
stages of sleep due to the advancements in technology since Rechtschaffen and Kales 
published their sleep scoring method.  They determined that loss of alpha activity is the 
best way to define the transition from wake to Stage 1 sleep. They also combined stage 3 
and 4, as defined by Rechtschaffen and Kales, into one stage thereby combining the two 
SWS stages.  They also put forth new rules to clearly define the presence of REM sleep. 
The new sleep stages according to the AASM are now labeled Stage W (wake), Stage 
N1, Stage N2, Stage N3, and Stage R (REM) (Silber et al., 2007). 
In healthy young adult humans, sleep occurs in cycles throughout the night.  Stage 
1 sleep begins the first cycle in the transition from waking and lasts several minutes 
before stage 2 sleep begins.  Stage 2 sleep can occur for approximately 10 to 25 minutes 
as the transition from light sleep in stage 1 to deeper sleep begins.  The end of stage 2 
sleep is signaled by the appearance of low frequency waves as deep slow wave sleep 
starts to predominate. Stage 3 sleep is a relatively short transitory stage into the long 
lasting (20-40 min) stage 4 slow wave sleep.  REM sleep brings about a slightly higher 
level of consciousness and in the first cycle of the night it will only last for up to 5 
minutes. Following REM, sleep stage 2 sleep occurs, and the cycle will repeat throughout 
the night. Sleep cycles take approximately 80-90 minutes to complete, and with more 
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cycles in a given night, time spent in SWS sleep will decrease, while time spent in stage 2 
and REM will increase (Carskadon & Dement, 1994). 
1.2.3 The Two-Process Model of Sleep Regulation 
 
Two separate yet equally important processes govern sleep (Borbely, 1982; Daan 
et al., 1984). The circadian process for sleep (Process C) is considered sleep independent 
and is primarily regulated by the suprachiasmatic nucleus in the hypothalamus.  The 
physiological process for sleep (Process S) is sleep dependent and can be represented by 
the activity of an electroencephalogram (EEG).  The interaction between these two 
systems determines when we feel the need to sleep, the length of sleep, and the 
progression through the sleep stages (Borbely, 1982; Daan et al., 1984; Achermann, 
2004). 
Most of life on earth has some dependence on the light/dark cycle that occurs in 
each 24-hour period as the earth rotates on its axis.  The word circadian in a Latin sense 
essentially means around the day in reference to a 24-hour period of time.  Evidence 
suggests that the generator of the circadian rhythm is the hypothalamic suprachiasmatic 
nucleus (SCN) (Moore & Eichler, 1972; Meijer & Rietveld, 1989; Ralph et al., 1990).  
The SCN responds to changes in the light dark cycle by receiving input from retinal 
ganglion cells that have axon projections to the SCN (Berson et al., 2002).  The influence 
of the circadian system on sleep pressure is associated with the release of melatonin from 
the pineal gland (Dijk 1997, Lavie 1997) with sleep occurring during times of melatonin 
release into the bloodstream.  However the SCN has efferent projections to multiple 
systems that can influence sleep pressure including the adrenergic, orexin, and 
serotonergic systems. Early studies also indicate that sleep propensity is also associated 
with the variance in body temperature with greater sleep pressure occurring with core 
body temperature is decreasing (Kleitman, 1933; Murray et al., 1958).  
Walter Cannon developed the term homeostasis essentially meaning a propensity 
of a body system to regulate the environment in a stable condition (Cannon, 1939).  In 
terms of sleep, homeostatic regulation applies to the length and depth of sleep over a 
period of time.  From the most basic standpoint, one might assume that as you are sleep 
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deprived you will compensate via extended sleep time to ensure sleep homeostasis. In 
contrast, studies have shown that recovery sleep time from extended periods of sleep 
deprivation do not properly account for the lost sleep.  One study demonstrated that 
following 90 hours of sleep deprivation, recovery sleep lasted 10 hours (Blake & Gerard, 
1937) while another reported 264 hours of sleep deprivation followed by 14.4 hours of 
recovery sleep (Gulevich et al., 1966).  These studies indicate that full recovery from 
long episode of sleep deprivation do not necessarily come from the length of recovery 
sleep.  While the body has mechanisms to ensure homeostasis, other areas of sleep 
structure play a role in recovery from sleep loss than just extended recovery sleep time. 
Researchers began to examine the quality of sleep to determine if parameters 
within sleep structure were involved in the recovery from sleep loss.  Several studies 
have also examined sleep onset, latency, and stage progression during sleep restriction 
protocols.  Sleep restriction refers to short sleep times over multiple days.  Evidence 
indicates that as sleep restriction progresses, subject’s level of perceived sleepiness 
increases, while sleep latency, stage 1, stage 2 and REM sleep are dramatically reduced, 
with the exception of the SWS stages, which remain unaltered (Webb & Agnew, 1975; 
Carskadon & Dement, 1981).  These results indicate that SWS may be the key to 
homeostatic recovery from sleep loss. SWS is more prominent in sleep cycles in the 
beginning of the night (Dement & Kleitman, 1957) and enhanced following sleep 
deprivation (Berger & Oswald, 1962).  Further studies indicate that excess sleep 
(Feinberg et al., 1980) or napping (Karacan et al., 1970) can cause a reduction in SWS in 
the subsequent night after sleep deprivation.  Spectral analysis of EEG in the low 
frequency range is considered a better indicator of SWS than scoring based on stages. 
Borbely et al. demonstrated that SWS, as quantified by power spectral analysis, was 
augmented during recovery sleep following 40.5 hours of sleep deprivation (Borbely et 
al., 1981). SWS is shortened following extended sleep, but enhanced following sleep 
deprivation, indicating it is a primary variable in the homeostatic model of sleep and can 
be used to indicate the propensity towards sleep in humans.   
In order to present the two-process model of sleep, the assumption must be made 
that Process C and Process S are independent of one another (Borbely, 1982; Daan et al., 
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1984). The best marker to visualize Process C is the rhythmic changes in body 
temperature throughout the day. Body temperature starts to descend in the evening 
illustrating an increase in the circadian propensity for sleep.  When body temperature is at 
its minimum point, the circadian pressure for sleep is at a maximum.  Process S, as 
defined as the need for SWS in a homeostatic sense, is at a minimum at waking.  Process 
S ascends during the day as the pressure for SWS increases and reaches a maximum 
when sleep is begun.   
1.3 Sleep Loss and Pain 
 
There is evidence from epidemiological studies indicating a link between chronic 
pain and sleep loss (Pilowsky et al., 1985; Atkinson et al., 1988; Moffitt et al., 1991; 
Morin et al., 1998; Power et al., 2005).  Pain is often considered the main variable 
resulting in the loss of total sleep time, and non-restorative sleep, in many different types 
of chronically painful conditions.  Evidence from cross-sectional studies utilizing 
polosomnography to examine sleep in patients with pain helps to further establish this 
link (Wittig et al., 1982; Raymond et al., 2001). 
Multiple studies have examined pain following total sleep deprivation of varying 
lengths.  The association between sleep loss and pain was first reported in 1934.  
Cooperman et al. published an uncontrolled study reporting a decrease in threshold for 
cutaneous pain as measured with von Frey hairs in six male subjects during a 60 hour 
sleep deprivation protocol (Cooperman et al., 1934).   In more recent years, the 
observations made by Cooperman have been supported using a variety sleep loss 
paradigms and methods of stimuli in humans (Onen et al., 2001; Kundermann et al., 
2004; Roehrs et al., 2006; Smith et al., 2007). 
Studies have also sought to examine the effects of selective sleep stage 
deprivation on the pain response in subjects with fibromyalgia.  In two separate studies, 
Moldofsky et al examined pain evoked by dolorimetry after selective sleep stage 
deprivation.  These studies provided evidence indicating that pain in patients suffering 
from fibromyalgia is elevated following stage 4 sleep deprivation (Moldofsky et al., 
1975), but unaltered following REM sleep deprivation (Moldofsky & Scarisbrick, 1976).  
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Several studies attempted to replicate the findings of Moldofsky but failed to see the 
same results.  In a sample of 19 subjects (13 treatment, 6 control), Older et al. failed to 
find any difference in pain threshold assessed by dolorimetry either within or between 
groups following stage 4 sleep deprivation (Older et al., 1998).  In contrast, Lentz et al. 
reported a decrease in pain threshold following slow wave sleep deprivation (stage 3 & 4) 
in a sample of 12 women.  It is important to note that this study did not include a control 
group (Lentz et al., 1999).  Whether in normal healthy subjects, or in patients suffering 
from fibromyalgia, sleep loss and sleep deprivation augment the pain response to many 
different types of stimulation in humans. 
1.4 Female Gonadal Hormones 
 
The female reproductive system involves cyclic changes in the ovaries and the 
uterus with each cycle lasting for approximately 28 days in normal non-pregnant females.  
The ovaries have a dual role in that they are responsible for production of the ovum and 
ovarian steroids.  The ovaries contain the primordial follicles that will ultimately become 
the oocyte.  In each cycle, several primordial follicles will begin the process of 
maturation into primary and then secondary follicles.   
The beginning of the ovarian and uterine cycles occurs with the release of 
gonadotropin releasing hormone (GnRH).  GnRH is secreted by the hypothalamus 
(Clayton, 1989) and operates by signaling the release of follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH) from the anterior pituitary gland (Schally et al., 
1971).  This period is termed the follicular phase and will last approximately 14 days.  
During the follicular phase the secondary follicles begin to secrete estrogen and a single 
secondary follicle will become the mature graffian follicle (McNatty et al., 1975).  The 
graffian follicle consists of several layers including the outer layer or theca externa, the 
inner layer or theca interna and a secretory layer termed the granulosa layer (Sanyal et 
al., 1974).  Estrogens will inhibit the release of further FSH and LH from the anterior 
pituitary and the less developed follicles will cease development (Goldenberg et al., 
1972).  Circulating estrogen in the blood also signals the uterus and the repair of the 
endometrium will begin.  The stratum basalis begins mitosis producing the stratum 
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functionalis resulting in a thickening of the endometrium. As the thickening of the 
endometrium occurs, endometrial glands are developed and the arterioles are extended 
into the stratum functionalis. 
Ovulation will occur approximately 14 days into the cycle.  Estrogen will reach a 
critical peak and, instead of inhibiting FSH and LH, it exerts positive feedback and 
causes the release of GnRH from the hypothalamus, which promotes a large release of 
LH and FSH (Goldenberg et al., 1972).  The “LH surge” will cause the graffian follicle to 
rupture and the secondary oocyte is released.  The Luteal phase begins with expulsion of 
the oocyte from the graffian follicle.  After exclusion of the oocyte, the graffian follicle 
undergoes the process of Luteinization whereby the therca interna cells and the granulosa 
cells mix forming first, the corpus hemorrhagicum, and then the corpus luteum.  The 
corpus luteum secretes a moderate amount of estrogen, but primarily secretes 
progesterone (McNatty et al., 1979).  The corpus luteum will degrade in approximately 2 
weeks if fertilization of the oocyte does not occur and levels of estrogen and progesterone 
will fall. The cells in the stratum functionalis of the endometrium will die and fall off 
resulting in menstrual flow.  Following menstruation, the cycle will repeat.  Figure 1.1 
demonstrates the relative hormonal fluctuations during the menstrual cycle.  Studies 
examining the effects of menstrual phase often will compare the early follicular (EF) and 
mid-luteal (ML) phases since these two phases allow for the largest difference in 
hormone levels. 
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Figure 1.2. Relative fluctuations in Luteinizing Hormone (LH) and the ovarian hormones 
Estradiol, and Progesterone across the menstrual cycle. EF, early follicular phase; ML, 
Mid-Luteal phase.  
1.4.1 Female gonadal hormones and pain 
 
The theory that menstrual cycle phase and sex hormone levels might alter the 
perception of experimentally induced pain in humans can be traced back to 1933.  Herren 
(1933) measured pressure pain threshold during three separate time points during the 
menstrual cycle.  The pre-menstruation measurement was taken 5 days prior to 
menstruation, the inter-menstruation measurement was taken within 3 days following the 
cessation of menstruation, and the post-menstruation measurement was recorded two 
weeks following the start of the last menstruation period.  The results of the study 
indicated that pressure pain threshold was decreased in the pre-menstrual phase 
indicating an elevated sensitivity to pain.  While the study failed to measure sex hormone 
concentration, they attributed their results to the higher hormone levels preceding 
menstruation. Robinson & Short (1977) examined the rhythmicity of pressure pain 
threshold on the breasts and noted that the peak occurred during pre-menstruation or 
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menstruation.  Other studies that have measured pain in response to pressure stimuli have 
noted that pain tolerance has been increased in the follicular phase (Kuczmierczyk & 
Adams, 1986) while others have demonstrated no difference (Amodei & Nelson-Gray, 
1989). Straneva et al. (2002) measurement of pain tolerance and threshold using other 
stimulus modalities has brought mixed results.  Ischemic pain tolerance and threshold 
have been demonstrated mixed results with some studies reporting an elevated pain 
response during the follicular phase (Fillingim et al., 1997; Pfleeger et al., 1997) but 
others report no difference (Amodei & Nelson-Gray, 1989; Sherman et al., 2005; 
Klatzkin et al., 2010)   
Studies examining thermal pain during the different phases of the menstrual cycle 
have demonstrated little difference between phases to heat pain (Fillingim et al., 1997; 
Granot et al., 2001; Klatzkin et al., 2010).  The cold pressor test has been used to study 
pain throughout the menstrual cycle and Hapidou & De Catanzaro (1988) reported a 
lower pain threshold during the luteal phase, but others have reported no difference in 
pain tolerance or threshold between phases (Veith et al., 1984; Klatzkin et al., 2010).   
However, ratings of pain intensity during the cold pressor test may provide a closer 
approximation to clinical pain, and the studies examining pain intensity based on a visual 
analog scale have reported elevated pain during the luteal phase (Hapidou & De 
Catanzaro, 1988; Stening et al., 2007).  Furthermore, Stening et al. (2007) demonstrated 
that rising progesterone levels with a static estradiol increased pain indicating the 
potential role progesterone serves in altering the pain response during the menstrual 
cycle. 
Although not all studies involving experimentally induced pain have reported 
differences between phases of the menstrual cycle, studies reporting differences all report 
an increase in pain sensitivity during the low hormone follicular phase.  The conflicting 
results may be due to in part stimulus modality or the timing of the menstrual cycle 
causing differences in when subjects were tested during the menstrual cycle. 
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1.4.2 Sleep, insomnia and gonadal sex hormones 
 
Insomnia is a disorder of hyper-arousal and is characterized by difficulty falling 
asleep, sleeping, or getting restorative sleep (Roth, 2007).  Evidence suggests that 
approximately 30% of the population may suffer from insomnia (Health, 2005).  
Insomnia has significant consequences and can severely impact quality of life in effected 
individuals.  Insomnia has been linked to an increased risk for the development of 
hypertension (Vgontzas et al., 2009a), diabetes (Vgontzas et al., 2009b), anxiety 
disorders and depression (Neckelmann et al., 2007).  Women are more likely to report 
insomnia (Klink et al., 1992; Soares, 2005; Sivertsen et al., 2009) and one potential 
contributing factor in the menstrual cycle.   
Studies suggest that subjective ratings of sleep quality are decreased during the 
Luteal phase of the menstrual cycle (Patkai et al., 1974; Manber & Bootzin, 1997; 
Shechter et al., 2010).  Despite the evidence indicating lesser quality sleep during the 
luteal phase, studies examining polysomnography across menstrual phase demonstrate 
little difference in sleep onset latency, slow wave sleep and sleep efficiency between 
phases (Driver et al., 1996; Baker et al., 2004).  Several studies demonstrate that REM 
sleep is decreased during the ML phase (Driver et al., 1996; Shechter et al., 2010) 
indicating alterations in the circadian process for sleep in the ML phase.  
Core body temperature demonstrates a diurnal rhythm with a maximum during 
the day and a minimum during the night and may be attributed to the release of melatonin 
(Cagnacci et al., 1992).  The propensity for sleep is highest when core body temperature 
reaches the daily minimum (Murray et al., 1958; Borbely, 1982). Evidence demonstrates 
that the menstrual cycle effects core body temperature resulting in a blunted nocturnal 
decline during the luteal phase (Lee, 1988; Cagnacci et al., 1992; Cagnacci et al., 1996; 
Shibui et al., 2000).  The blunted nocturnal body temperature during the luteal phase of 
the menstrual cycle indicates a disruption in the circadian process of sleep (Shibui et al., 
2000) that has implications for the decrease in sleep quality reported during the luteal 
phase.  
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1.5 Summary and Hypothesis 
 
Pain and sleep share a complex relationship that appears to be bi-directional.  
Chronic pain often results in poor quality sleep, or total loss of sleep, and yet, it’s been 
widely reported that sleep loss heightens sensitivity to pain.  Studies examining pain 
following sleep deprivation have not examined pain intensity during a sustained protocol.  
Study 1 examines the effects of 24-hour total sleep deprivation on ratings of pain 
intensity during the cold pressor test in men and women.  We hypothesized that 24-
hour total sleep deprivation would augment pain intensity.  Evidence suggests that 
women are more sensitive to painful stimuli, therefore, we further hypothesized that 
ratings of pain intensity would be higher in women compared to men.  Insomnia is 
more prevalent in women compared to men and the menstrual cycle may play a role in 
mediating sleep loss in women.  Gonadal sex hormones levels fluctuate during the 
menstrual cycle and may also contribute to alterations in the pain response across 
menstrual phase.  Study 2 examines pain intensity during the early follicular and mid-
luteal phases of the menstrual cycle in females.  We hypothesized that pain intensity 
would be augmented during the ML phase of the menstrual cycle following 24-hour 
total sleep deprivation in females. 
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Chapter 2 Study 1 
2.1 Introduction 
 
Patients suffering chronic pain report poor quality sleep and loss of sleep time 
(Wittig et al., 1982; Smith et al., 2000).  However, studies report that sleep loss leads to 
hyperalgesia and an augmentation of pain (Cooperman et al., 1934; Kundermann et al., 
2004; Roehrs et al., 2006).  There is considerable evidence indicating sex differences in 
pain intensity ratings to thermal noxious stimuli with females reporting higher intensity 
than males (al'Absi et al., 2002; Lowery et al., 2003; Kim et al., 2004).  However, studies 
reporting sex differences to cold thermal pain remain equivocal with several studies 
reporting sex differences (Myers et al., 2001; Lowery et al., 2003; Edwards et al., 2004; 
Keogh et al., 2005) and others reporting no difference (Keogh et al., 2000; Jones et al., 
2003; Pud et al., 2006).  To date, studies examining pain following sleep deprivation 
have focused on pain threshold as the primary outcome variable with all reporting a 
decrease in threshold following sleep deprivation (Cooperman et al., 1934; Moldofsky & 
Scarisbrick, 1976; Onen et al., 2001; Kundermann et al., 2004), yet no between sex 
comparison has been performed.   
Sustained cold noxious stimuli has been demonstrated to produce greater pain 
ratings that more closely mimic clinical pain conditions than pain threshold analysis 
(Rainville et al., 1992).  Therefore we relied upon the cold pressor test to examine pain 
intensity following 24-hour total sleep deprivation (TSD).  Given the evidence supporting 
a decrease in pain threshold following sleep deprivation, and data indicating sex 
differences to cold noxious stimuli, the purpose of this study was to determine the 
effects of TSD on thermal pain perception. We hypothesized that TSD would augment 
pain perception during a 2-minute cold pressor test, and females would report higher pain 
intensity than males.   
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2.2 Methods 
2.2.1 Subjects 
 
Thirty healthy subjects (15 men and 15 women) enrolled in the study.  All 
subjects reported to be nonsmokers with no history of cardiovascular disease, autonomic 
dysfunction, asthma, or diabetes.  All female subjects were free of oral contraceptive use, 
reported regular menstrual cycles (range 26-30 days), and were tested during the early 
follicular phase of the menstrual cycle.  One female subject was excluded from the study 
when hormone data indicated she was not in the early follicular phase for one testing 
session.  All subjects were screened for obstructive sleep apnea by a board certified sleep 
physician (J. DellaValla) using the at home ApneaLink (Resmed, San Diego, CA).  
Exclusion from the study occurred when the apnea-hypopnea index was ≥10 arbitrary 
units and one male subject was excluded on this basis.  Additionally, one female subject 
was excluded due to failure to complete the testing session resulting in a total sample size 
of 27 (14 men and 13 women).  All subjects participated in an orientation session before 
providing written informed consent.  This study was approved by the Michigan 
Technological University Institutional Review Board. 
2.2.2 Experimental Design 
   
  Two testing sessions were performed, one following a normal night of sleep at 
(NS), and one following 24-hour total sleep deprivation.  Subjects were tested 
approximately one month apart to allow for females to be tested during the early 
follicular phase of the menstrual cycle.  Trial order (NS vs. TSD) was randomized to 
obtain a balanced crossover design.  Sleep time for 3 days preceding the study was 
monitored with wrist actigraphy (Actiwatch 64 Respironics Inc, Bend OR) to ensure 
subjects were getting adequate sleep.   
  The day prior to the TSD trial subjects were contacted at 7:00 a.m. and instructed 
to refrain from napping during the day.  They reported to the laboratory at 11 p.m. where 
two assistants ensured they did not sleep during the night.  Subjects refrained from 
caffeine, alcohol and exercise for 12 hours, and fasted for 8 hours prior to testing.   
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2.2.3 Protocol 
   
  Testing proceeded in both conditions starting at 7:00 a.m. with 3 consecutive 
recordings of resting blood pressure (~1 minute apart) with an automated 
sphygmomanometer (Omron HEM-907XL, Omron Health Care) following 5 minutes of 
seated rest.  Following a standard breakfast, subjects assumed a supine position on the 
testing table for instrumentation.  Micronreurography was performed to obtain pulse 
synchronous bursts of muscle sympathetic nerve activity (MSNA).  Heart rate was 
measured continuously with a 3-lead electrocardiogram.  Continuous beat-to-beat blood 
pressure was measured using a Finometer (Finapres Medical Systems, Amsterdam, The 
Netherlands).  Three consecutive recordings of supine blood pressure were recorded 
immediately preceding the baseline to calibrate the Finometer.  Blood pressure was 
expressed as systolic arterial pressure (SAP), diastolic arterial pressure (DAP), and mean 
arterial pressure (MAP). 
   Following instrumentation, subjects lay quietly for an initial 10-minute baseline 
followed by 3 valsalva maneuvers separated by a one-minute recovery.  Subjects were 
instrumented with venous occlusion plethysmography and a new 5-minute baseline was 
obtained followed by 5 minutes of mental arithmetic and a 10-minute recovery.  This 
thesis focuses on the third and final intervention, the cold pressor test. A 3-minute 
baseline was recorded followed by a 2-minute cold pressor test.  Briefly the subject’s 
hand was immersed up to the wrist in ice water (~1°C).  Ratings of perceived pain were 
recorded every 15 seconds by having the subject declare a pain level from a modified 
Borg scale situated in their field of view.  A final 3-minute recovery period was recorded 
following the cold pressor test. 
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2.2.4 Statistical Analysis 
 
All statistical analyses were performed using commercial software (SPSS 20.0, 
SPSS, Chicago, IL).  We used repeated-measures ANOVA with condition (NS vs. TSD) 
as the within-subjects factor and sex (men vs. women) as the between-subjects factor.  
Post-hoc analysis with paired t-tests was done when significant condition by sex 
interactions in baseline data, and significant condition by time interactions for the cold 
pressor test were observed. Results are expressed as mean ± SE.  Significant differences 
were noted at p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26  
2.3 Results 
2.3.1 Baseline Responses 
 
Table 2.1 displays subject characteristics and mean values for resting blood 
pressure following both NS and TSD conditions.  Blood pressure, expressed as SAP, 
DAP and MAP, were elevated following TSD in both men and women (condition, 
P<0.01).  Baseline hemodynamic data has been reported and discussed (Carter et al., 
2012).  Sleep time for the three nights preceding the study was not different between NS 
(7.3 ± 0.2 h in men and 7.6 ± 0.2 h in women) and TSD (7.6 ± 0.3 h in men and 7.5 ±0.3 
h in women) conditions. 
 
Table 2.1. Baseline values for men and women following normal sleep and 24-hour total 
sleep deprivation. 
 
Men Women P Value 
Variable NS TSD NS TSD Condition Sex 
Condition 
× Sex 
Age, years 22±1  -- 22±1 -- -- -- -- 
Height, cm 176±2 -- 165±2 -- -- -- -- 
Weight, kg 79±4 79±4 63±3 64±3 P=0.48 P<0.01 P=0.18 
SAP, mmHg 109±2 115±2 97±2 98±2 P<0.01 P<0.05 P<0.03 
DAP, mmHg 58±2 61±1 56±1 59±2 P<0.01 P=0.36 P=0.33 
MAP, mmHg 75±1 79±1 70±1 72±1 P<0.01 P<0.01 P=0.24 
Estradiol, 
pg/ml 
24.8±2.0 20.4±0.9 36.7±9.0 29.9±2.8 P= 0.06 P=0.03 P=0.4  
Progesterone, 
ng/ml 
2.15±0.17 1.80±0.15 2.11±0.19 1.33±0.14 P <0.01 P = 0.12 P<0.05 
Values are mean ± SE. n=14 men and n=13 unless otherwise noted; NS, normal sleep; 
TSD, total sleep deprivation; SAP, systolic arterial blood pressure; DAP, diastolic arterial 
blood pressure; MAP, mean arterial blood pressure. Estradiol and Progesterone, n=26 (14 
men and 12 women). 
 
 
 
 27  
 
 
2.3.2 Pain Responses 
 
Figure 2.1 demonstrates that pain intensity increased during CPT following both 
NS and TSD conditions (time, p<0.05), and that pain intensity was augmented following 
TSD when compared to NS  (Δ1.23 a.u. time x condition, p<0.05).  The augmented pain 
response to CPT following TSD was noted when pain intensity was expressed as mean 
(NS 6.95 ±0.5 vs. TSD 8.18 ±0.5, condition, p<0.01) or peak pain intensity (NS 8.91 ±0.6 
vs. TSD 10.22 ±0.5, condition, p<0.01) as displayed in Figure 2.2.  Figure 2.3 
demonstrates that there was no sex differences in the pain intensity during CPT in either 
NS or TSD sleep condition (condition x time x sex, p>0.05).  There was no correlation 
between changes in pain intensity and sex hormone levels following TSD. 
 
 
Figure 2.1. Changes in pain intensity during 2-minute cold pressor test following normal 
sleep (NS) and 24-hour total sleep deprivation (TSD).  TSD augmented (~Δ1.2 a.u.) the 
pain intensity response to CPT.  *p<0.05 NS vs TSD. 
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Figure 2.2  Changes in mean and peak pain intensity during 2-minute cold pressor test 
(CPT) following normal sleep (NS) and (TSD).  TSD elevated the mean and peak pain 
response to CPT.  *p<0.05 NS vs TSD. 
 
 
 
 
 
Figure 2.3.  Mean changes in pain intensity during 2-minute cold pressor test (CPT) in 
men and women.  There were no sex differences in the pain intensity responses during 
CPT following normal sleep (NS) and total sleep deprivation (TSD).  *p<0.05 CPT vs. 
baseline. 
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2.4 Discussion 
 
The current study examined the influence of 24-hour TSD on pain intensity 
during CPT, and we report two novel findings.  First, TSD augmented pain intensity 
responses during CPT. Second, contrary to our hypothesis, there were no sex differences 
in the pain intensity response to CPT. The use of a sustained stimulus to elicit pain 
provides a closer approximation to clinical pain than other measure such as threshold 
analysis. 
 Previous studies suggest that sleep deprivation or sleep loss results in an 
augmented pain response in healthy subjects (Cooperman et al., 1934; Onen et al., 2001; 
Kundermann et al., 2004; Roehrs et al., 2006; Azevedo et al., 2011).  Hyperalgesia has 
also been demonstrated following sleep loss in patients suffering from fibromyalgia 
(Moldofsky et al., 1975; Lentz et al., 1999) although not all studies support this finding 
(Older et al., 1998).  The testing paradigms demonstrating hyperalgesia following sleep 
loss indicate an increased sensitivity to mechanical and heat stimuli, however, only one 
study included noxious cold stimuli following sleep loss and reported a trend towards an 
augmented pain response when examining pain threshold (Kundermann et al., 2004).  
The current study demonstrates that 24-hour TSD augments the pain intensity response to 
sustained noxious cold thermal stimuli. 
 It is well established that sleep loss augments mechanical pain perception in 
humans (Cooperman et al., 1934; Onen et al., 2001), but the effects on thermal pain are 
less clear, and little attention has been paid to cold stimuli.  Kundermann et al. (2004) 
examined heat and cold pain threshold utilizing a protocol with two TSD nights separated 
by two recovery nights.  They reported a decrease in heat pain threshold following TSD 
and a trend for a decrease in cold pain threshold.  Further studies examining noxious heat 
stimuli have since supported the notion that sleep loss augments the heat pain response in 
humans (Roehrs et al., 2006; Azevedo et al., 2011).  Kundermann et al. (2004) only 
reported a trend towards a decrease in cold pain threshold following sleep deprivation, 
whereas the current study demonstrated a significant increase in pain intensity during 
noxious cold stimuli.   
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The variability in pain results following sleep deprivation may be due to stimulus 
modality.  The augmented mechanical and heat pain response following sleep deprivation 
is well established through studies examining pain threshold analysis.  Mechanical and 
heat nociceptors primarily fall in the A-delta category and are involved in the fast pain 
response making them ideally suited for threshold analysis.  However, cold pain is 
primarily carried by slow C-fibers, making it less suitable for threshold analysis.  
Whereas Kundermann et al. (2004) only noted a trend towards a decrease in cold pain 
threshold involving a brief stimulus, the current study demonstrated a robust 
augmentation in pain intensity to sustained cold stimuli following TSD.  The difference 
between the current study and Kundermann et al. (2004) may be due to the stimulus 
modality.  We believe that a sustained stimulus provides a more accurate representation 
of the perception of cold pain than threshold analysis.  Furthermore, sustained painful 
stimuli may provide a closer approximation to clinical pain than threshold analysis 
(Rainville et al., 1992). 
Evidence suggests that the pain response to noxious stimuli varies between the 
sexes, and that women generally report more pain than men.  Contrary to our hypothesis, 
the current study demonstrated no sex differences in pain intensity during CPT following 
either sleep condition.  While the many studies report sex differences to noxious cold 
stimuli (Myers et al., 2001; Lowery et al., 2003; Sarlani et al., 2003; Edwards et al., 
2004; Keogh et al., 2005; Nielsen et al., 2008), the data are variable and studies also 
report no sex differences (Keogh et al., 2000; Jones et al., 2003; Tousignant-Laflamme et 
al., 2005; Pud et al., 2006).   The current study suggests that the factors mediating a 
differential pain response between the sexes are not significantly influence by TSD. 
Kundermann et al. (2004) examined thermal sensitivity to determine if a change 
in overall somatosensory sensitivity was responsible for hyperalgesia following TSD.  
Their results indicate that thermal sensitivity was not altered by TSD and therefore, the 
changes in pain threshold were due to mechanisms other than a change in overall, general 
somatosensory sensitivity.  The question then arises as to what is responsible for the 
change in pain perception after sleep loss.  Studies in animals suggest a possible 
impairment in the endogenous opioid system (Ukponmwan et al., 1984; Fadda et al., 
 31  
1991) contributing to an augmented pain response. Furthermore, Smith et al. (2007) used 
a diffuse noxious inhibitory control (DNIC) protocol following partial sleep deprivation 
and demonstrated a reduction in pain inhibitory capacity.  These results suggest an 
alteration in pain inhibition following sleep deprivation that is often attributed to 
endogenous opioids.  A recent study examining pain and sleep deprivation in humans 
also demonstrated an increase in prostaglandins following sleep deprivation (Haack et al., 
2009).  The prostaglandin system is a mediator in the inflammatory response including 
inflammation-mediated pain symptoms.    Haack et al. (2009) attributed the elevated pain 
response to an increase in prostaglandins and described both peripheral and central 
actions of the prostaglandin system that potentially mediate hyperalgesia following sleep 
deprivation.  The mechanisms responsible for hyperalgesia following sleep loss require 
more attention with a greater emphasis on data from human subjects. 
In summary, 24-hour TSD increased pain intensity responses during CPT. The 
augmented pain response to sustained noxious cold stimuli following TSD extends the 
findings provided by pain threshold analysis in that extended exposure to painful stimuli 
provides a closer association to clinical pain (Rainville et al., 1992).  Sustained painful 
stimuli are usually present in chronic painful disease conditions, and the results of this 
study indicate that measures should be taken to ensure these patients receive adequate 
sleep. 
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Chapter 3 Study 2 
3.1 Introduction 
 
Studies indicate that 30% of the population may suffer from insomnia (Health, 
2005; Roth, 2007), and evidence suggests it’s more prevalent in women compared to men 
(Soares, 2005; Sivertsen et al., 2009).  Subjective sleep quality and alertness are 
decreased during the ML phase of the menstrual cycle (Manber & Bootzin, 1997; 
Shechter et al., 2010) indicating a potential contributing factor to the increased 
prevalence of insomnia in women.  Reports suggest that sleep loss leads to hyperalgesia 
(Kundermann et al., 2004; Roehrs et al., 2006) and pain intensity is increased in the 
Luteal phase of the menstrual cycle (Hapidou & De Catanzaro, 1988; Stening et al., 
2007) demonstrating a possible link between menstrual phase and an increased risk for 
insomnia in women.  Therefore, the purpose of this study was to determine the effects 
of TSD on thermal pain perception during the early follicular and mid luteal phases 
of the menstrual cycle in women.  We hypothesized that pain perception during a 2-
minute cold pressor test would be augmented in the mid luteal phase of the menstrual 
cycle. 
3.2 Methods 
3.2.1 Subjects 
 
Ten healthy women were enrolled in the study.  All subjects reported to be 
nonsmokers with no history of cardiovascular disease, autonomic dysfunction, asthma, or 
diabetes.  Female subjects were free of oral contraceptive use, and reported regular 
menstrual cycles (range 26-30 days).   All subjects participated in an orientation session 
before providing written informed consent.  This study was approved by the Michigan 
Technological University Institutional Review Board. 
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3.2.2 Experimental Design 
   
  Two testing sessions were performed, both following 24-hour total sleep 
deprivation (TSD) in the lab.  Subjects were tested once during the early follicular phase 
of the menstrual cycle (2-5 days following onset of menstruation), and once during the 
mid-luteal phase of the menstrual cycle (8-10 days following the LH surge). Trial order 
(EF vs. ML) was randomized to obtain a balanced crossover design.  Sleep time for 3 
days preceding the study was monitored with wrist actigraphy (Actiwatch 64 Respironics 
Inc, Bend OR) to ensure subjects were getting adequate sleep.   
  The day prior to each testing session subjects were contacted at 7:00 a.m. to 
ensure they were awake and instructed to refrain from napping during the day.  They 
reported to the laboratory at 11 p.m. where two assistants ensured they did not sleep 
during the night.  Subjects refrained from caffeine, alcohol and exercise for 12 hours, and 
fasted for 8 hours prior to testing.   
3.2.3 Protocol 
   
  Testing proceeded in both conditions starting at 7:00 a.m. with 3 consecutive 
recordings of resting blood pressure (~1 minute apart) with an automated 
sphygmomanometer (Omron HEM-907XL, Omron Health Care) following 5 minutes of 
seated rest.  Following a standard breakfast, subjects assumed a supine position on the 
testing table for instrumentation.  Microneurography was performed to obtain pulse 
synchronous bursts of MSNA.  Heart rate was measured continuously with a 3-lead 
electrocardiogram.  Continuous beat-to-beat blood pressure was measured using a 
Finometer (Finapres Medical Systems, Amsterdam, The Netherlands).  Three consecutive 
recordings of supine blood pressure were recorded immediately preceding the baseline to 
calibrate the Finometer.  Blood pressure was expressed as systolic arterial pressure 
(SAP), diastolic arterial pressure (DAP), and mean arterial pressure (MAP). 
  Following instrumentation, subjects lay quietly for an initial 10-minute baseline.  
Subjects were then instrumented for venous occlusion plethysmography and a new 5-
minute baseline was obtained followed by 5 minutes of mental arithmetic and a 10-
minute recovery.  This thesis focuses on the third and final intervention, the cold pressor 
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test. A 3-minute baseline was recorded followed by a 2-minute cold pressor test.  Briefly 
the subject’s hand was immersed up to the wrist in ice water (~1°C).  Ratings of 
perceived pain were recorded every 15 seconds by having the subject declare a pain level 
from a modified Borg scale situated in their field of view.  A final 3-minute recovery 
period was recorded following the cold pressor test. 
3.2.4 Statistical Analysis 
   
 All statistical analyses were performed using commercial software (SPSS 20.0, SPSS, 
Chicago, IL).  Baseline variables were compared using paired t-tests.  We used repeated-
measures ANOVA with condition (EF vs. ML) as the within-subjects factor for 
comparisons during the cold pressor test. Results are expressed as mean ± SE.  
Significant differences were noted at p<0.05. 
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3.3 Results 
3.3.1 Baseline Responses 
 
Table 3.1 demonstrates seated resting blood pressure recordings and female 
gonadal hormone concentrations.  Subject weight and body mass index (BMI) was 
unchanged between the two testing sessions and resting blood pressure was not different 
between the two phases of the menstrual cycle.  Importantly, estradiol and progesterone 
concentrations were significantly higher during the ML phase of the menstrual cycle.  
Finally, sleep time for the three nights preceding the study was not different between the 
EF (7.3 ± 0.3 h) and ML (7.2 ± 0.2 h) phases. 
 
Table 3.1. Resting variables for early follicular and mid-luteal testing sessions. 
 
Variable EF ML 
Age (years) 21±1 -- 
Height (cm) 166±2 -- 
Weight (kg) 71±16 71±16 
BMI (kg/m2) 26±2 26±2 
SAP (mmHg) 105±5 107±5 
DAP (mmHg) 69±4 65±4 
MAP (mmHg) 81±4 79±4 
HR (mmHg) 62±3 62±2 
Estradiol (pg/ml) 28.6±2.9 65.7±9.9* 
Progesterone (ng/ml) 1.47±0.21 4.9±1.05* 
Values are mean ± SE; n=10; EF, Early Follicular; ML, Mid-Luteal; BMI, body mass 
index; SAP, systolic arterial pressure; DAP, diastolic arterial pressure; MAP, mean 
arterial pressure; HR heart rate; * P < 0.05, EF vs. ML. 
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3.3.2 Pain Responses 
 
Figure 3.1 demonstrates that pain intensity increases during CPT in both the EF 
and ML phase of the menstrual cycle (time, p<0.05) however there was no difference in 
pain intensity ratings between the two cycles (time x condition, p = 0.48).  Similarly, 
figure 3.2 displays that there were differences in the mean or peak pain response between 
the EF and ML phase of the menstrual cycle.  There was no correlation between pain 
intensity and sex hormone levels following either condition. 
 
 
Figure 3.1. Changes in pain intensity during 2-minute cold pressor test during EF and 
ML phases of the menstrual cycle following 24-hour total sleep deprivation (TSD).  Pain 
intensity was not different between the two phases of the menstrual cycle following TSD. 
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Figure 3.2. Changes in mean and peak pain intensity during 2-minute cold pressor test 
(CPT) during EF and ML phases of the menstrual cycle following 24-hour total sleep 
deprivation (TSD).  Menstrual phase did not alter the average pain intensity or peak pain 
intensity following TSD.   
 
3.4 Discussion 
 
The current study examined the influence of thermal pain perception following 
TSD during two phases of the menstrual cycle.  Contrary to out hypothesis, the results or 
our study indicate that pain intensity during the cold pressor test after TSD is not 
different between the EF and ML phases of the menstrual cycle.  Our findings suggest 
that collectively, TSD and menstrual phase do result in a differential pain response 
between the EF and ML phase of the menstrual cycle. 
To date, studies have not examined the combined effect of sleep deprivation and 
menstrual phase on experimentally induced pain.  Evidence indicates that sleep loss alone 
augments perceived pain responses (Onen et al., 2001; Kundermann et al., 2004; Roehrs 
et al., 2006; Smith et al., 2007), and several studies have demonstrated that pain 
sensitivity may be elevated in the luteal phase of the menstrual cycle (Kuczmierczyk & 
Adams, 1986; Hapidou & De Catanzaro, 1988; Fillingim et al., 1997; Pfleeger et al., 
1997; Stening et al., 2007). They attribute this response to elevated gonadal hormone 
levels, particularly progesterone. Despite the independent effects of TSD and menstrual 
phase on perceived pain, the current study did not demonstrate any difference in pain 
intensity between the EF and ML phases of the menstrual cycle following TSD.   This 
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study provides an indication that collectively TSD and elevated gonadal hormone levels 
do not result in a differential pain response between menstrual phases. 
Women are more sensitive to pain compared to men (Myers et al., 2001; Lowery 
et al., 2003; Klatzkin et al., 2010) and one potential mediator of these differences in the 
variability of sex hormone levels during the menstrual cycle in females.  Studies 
examining pain across menstrual phase have demonstrated conflicting results.  Results 
from animal studies demonstrate an altered pain response with fluctuations in gonadal 
hormone levels and most demonstrate elevated pain sensitivity during high hormone 
phases (Molina et al., 1990; Frye et al., 1993; Martinez-Gomez et al., 1994; Kayser et al., 
1996).  Contrary to results from animal studies, human experiments examining 
experimentally induced pain from heat, ischemia, and pressure across the menstrual cycle 
have not demonstrated consistent results (Amodei & Nelson-Gray, 1989; Fillingim et al., 
1997; Pfleeger et al., 1997; Granot et al., 2001; Straneva et al., 2002; Sherman et al., 
2005; Klatzkin et al., 2010) although studies that do report a difference, demonstrate 
enhance pain sensitivity during high hormone phases.  Variability in the stimulus 
modality, experimental procedure, or definition of menstrual phase may account for the 
conflicting results. 
Several recent studies have examined pain induced by the cold pressor test across 
menstrual phase.  Klatzkin et al. (2010) and Kowalczyk et al. (2006) demonstrated no 
difference in pain threshold or tolerance during the cold pressor between the EF and ML 
phase in a large sample of women, however, these studies differ from the current study in 
that they did not include a TSD protocol.  Stening et al. (2007) measured pain tolerance, 
pain activation time, and maximal pain during the cold pressor test across the menstrual 
cycle.  The only positive finding they reported was that pain activation time (AT), the 
amount of time it takes for pain to reach moderate levels, was decreased in the late luteal 
phase of the menstrual cycle.  They further demonstrated that the decrease in AT was 
more pronounced in periods where progesterone was rising while estradiol remained 
constant and when estradiol concentrations were rising the diminished AT response to 
progesterone was decreased.  Estradiol and progesterone levels were both substantially 
elevated in our study, however, there was no correlation between ratings of pain intensity 
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and hormone levels. Similar to our study, Stening et al. (2007) reported no difference in 
pain intensity rated from a visual analog scale across the menstrual cycle.   Furthermore, 
while AT may be used as an index of pain threshold, the method utilized to determine AT 
has not been prevalent in similar study designs.  
Sleep deprivation and sleep loss result in heightened pain sensitivity 
(Kundermann et al., 2004; Roehrs et al., 2006), yet more studies are needed to 
understand the contributing mechanisms.  Studies in animals (Ukponmwan et al., 1984; 
Fadda et al., 1991) and humans (Smith et al., 2007) point to an inhibition of the 
endogenous opioid system following sleep deprivation.  Smith et al. (2006) demonstrated 
that high levels of estrogen were associated with elevated activation of endogenous 
opioid neurotransmission, whereas low levels of estrogen resulted in an attenuation of 
endogenous opioids in females.  They also demonstrated a correlation between 
endogenous opioid activity and pain perception.  These results suggest that perhaps the 
variability of estrogen may have a strong influence on perceived pain.  In the current 
study we demonstrated an increase in estrogen and progesterone in the ML phase of the 
menstrual cycle, but the increase was less than several similar studies (Kowalczyk et al., 
2006; Stening et al., 2007; Klatzkin et al., 2010).  This may provide an explanation as to 
why we failed to see a difference in pain intensity between the two phases. In Study 1 
presented in chapter 2, estradiol demonstrated a modest by not statistically significant 
decrease following TSD whereas we observed that progesterone levels were decreased 
following TSD.  This provides a possible explanation for the blunted hormone levels 
during the ML phase of the current study.  Therefore, the combined effect of sleep 
deprivation and menstrual phase may not have induced any collective effect. 
 In conclusion, we demonstrated that there was no difference in the pain intensity 
response to the cold pressor test between the EF and ML phases of the menstrual cycle 
following TSD.  Independently, sleep loss and menstrual phase may alter pain sensitivity, 
but collectively, they do not result in a differential pain response. 
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Chapter 4 Summary, Limitations, and Future Directions 
4.1 Summary 
 
Sleep loss and pain have a bi-directional relationship whereby loss of sleep 
augments pain and pain contributes to sleep loss.  This relationship has dire consequences 
for patients suffering from chronic pain.  In Study 1 we demonstrated an augmented pain 
response to sustained painful stimuli following TSD, however, we did not observe any 
sex differences.  This is the first study to examine TSD induced pain during sustained 
noxious stimulation.  Protocols relying on sustained noxious stimuli provide a closer 
approximation to clinical pain that threshold analysis (Rainville et al., 1992).  Therefore, 
TSD augments pain intensity during CPT, however, contrary to our secondary 
hypothesis, there were no sex differences. 
There is higher prevalence of insomnia in women and one potential mediator is 
gonadal sex hormones.  In Study 2 we demonstrated that the combined effect of TSD and 
elevated gonadal hormones did not result in a differential pain response between the EF 
and ML phases of the menstrual cycle.  While these findings were contrary to our 
hypothesis, this is the first study to examine the collective effects of TSD and menstrual 
phase on pain intensity.   
4.2 Limitations and Future Work 
 
One potential limitation is that we only measure pain evoked by one type of 
stimulus.  Future studies involving sleep deprivation and pain should involve the 
assessment of more than one type of stimuli since pain responses can vary depending on 
the stimulus modality due to the numerous types of nociceptors.  Post-exercise muscle 
ischemia is another method for assessing sustained pain in human subjects and could be 
included in future protocols.  Another potential limitation is that we did not have a 
comparison for sleep deprivation during the ML phase of the menstrual cycle.  While 
estradiol and progesterone levels were elevated during the ML phase, they did not reach 
levels comparable to similar studies following normal sleep.  Study 1 gives us an 
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indication that progesterone levels may be decreased following TSD and the ability to 
determine the effects of TSD during the ML phase could be beneficial. 
Study 2 was the first to examine the collective effects of TSD and menstrual 
phase on pain intensity.  The interactions between sleep and hormones are complex, and 
future work should include a DNIC protocol to investigate the effects of hormones and 
sleep deprivation the endogenous opioid system.  Finally, while sleep deprivation 
provides a model to assess the effects of sleep loss, sleep restriction may provide a closer 
approximation to sleep loss in healthy subjects, and disease states.  Future studies 
involving sleep loss and pain should include a sleep restriction protocol. 
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Appendix A: Raw data for Study 1 
 
Table A.1. Anthropometric data 
 
   
Normal Sleep 24-Hour Total Sleep Deprivation 
Subj-
ect Sex 
Age 
(yrs) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kg/m2) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kg/m2) 
1 F 22 168.0 73.5 26.04 167.0 73.2 26.25 
2 M 36 187.0 94.0 26.88 187.0 94.2 26.94 
3 M 20 183.0 100.5 30.01 182.0 100.0 30.19 
4 M 21 170.0 81.5 28.20 170.0 79.8 27.61 
5 M 26 169.0 59.5 20.83 170.0 60.0 20.76 
6 M 20 175.0 85.0 27.76 175.5 84.6 27.47 
7 M 18 180.0 91.0 28.09 180.0 91.5 28.24 
8 M 20 168.5 61.8 21.77 167.5 61.4 21.88 
9 M 18 173.0 63.0 21.05 173.0 62.0 20.72 
10 M 19 173.0 64.5 21.55 173.0 64.5 21.55 
11 M 20 189.0 95.5 26.73 189.0 96.0 26.87 
12 M 19 181.0 85.5 26.10 181.0 86.0 26.25 
13 F 25 173.0 62.0 20.72 155.0 54.0 22.48 
14 F 19 172.5 71.0 23.86 171.0 61.7 21.10 
15 M 19 173.0 70.0 23.39 173.0 70.5 23.56 
16 F 18 160.0 50.5 19.73 159.5 50.5 19.85 
17 F 18 160.0 63.0 24.61 160.0 62.5 24.41 
18 F 18 162.0 63.5 24.20 160.0 63.5 24.80 
19 F 28 171.0 97.0 33.17 170.5 96.0 33.02 
20 F 23 169.5 63.5 22.10 168.5 67.5 23.77 
21 F 24 160.0 53.0 20.70 158.0 53.5 21.43 
22 M 23 178.0 94.0 29.67 176.0 94.0 30.35 
23 M 24 167.5 65.0 23.17 167.0 64.5 23.13 
24 F 26 159.5 57.0 22.41 159.5 58.0 22.80 
25 F 27 176.0 60.5 19.53 175.0 61.0 19.92 
26 F 19 165.5 53.5 19.53 163.5 53.5 20.01 
27 F 19 167.5 72.5 25.84 167.5 74.5 26.55 
         
M, Male; F, Female; BMI, Body Mass Index 
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Table A.2. Raw data for seated resting blood pressure (mmHg) and heart rate (beats/min). 
 
 
Normal Sleep 24-Hour Total Sleep Deprivation 
Subject SAP DAP MAP HR SAP DAP MAP HR 
1 104.0 63.0 76.7 50.3 92.0 50.0 64.0 47.3 
2 104.0 59.3 74.2 53.3 126.7 67.7 87.4 47.3 
3 118.0 54.0 75.3 51.3 111.7 61.0 77.9 67.0 
4 118.7 70.0 86.2 73.3 106.0 66.0 79.3 55.7 
5 107.3 73.7 84.9 65.7 107.0 69.0 81.7 53.0 
6 116.3 86.3 96.3 85.7 108.0 75.0 86.0 67.3 
7 105.7 60.0 75.2 45.6 110.0 64.0 79.3 42.0 
8 105.7 56.7 73.0 55.0 117.0 71.7 86.8 55.0 
9 99.0 60.7 73.5 63.3 104.7 56.3 72.4 59.3 
10 96.3 63.7 74.6 81.0 105.0 74.0 84.3 73.0 
11 112.3 62.0 78.8 69.7 113.7 66.7 82.4 53.0 
12 121.3 67.7 85.6 52.0 115.0 63.7 80.8 55.0 
13 90.0 63.0 72.0 73.0 102.3 74.3 83.6 57.0 
14 102.0 76.3 84.9 87.7 105.0 74.3 84.5 61.7 
15 116.0 58.0 77.3 71.3 126.7 66.7 86.7 48.0 
16 90.0 59.3 69.5 81.3 103.3 70.3 81.3 59.0 
17 93.0 44.0 60.3 57.0 102.3 60.0 74.1 59.0 
18 101.3 62.0 75.1 71.3 111.3 63.3 79.3 63.0 
19 114.3 77.0 89.4 87.3 113.0 73.0 86.3 61.0 
20 108.7 77.7 88.0 59.3 115.7 81.0 92.6 47.0 
21 97.0 70.0 79.0 65.0 96.3 66.3 76.3 58.3 
22 107.3 60.0 75.8 52.3 120.7 71.7 88.0 64.3 
23 94.7 68.0 76.9 75.7 110.0 85.0 93.3 55.0 
24 88.7 57.3 67.8 77.0 89.7 57.3 68.1 65.3 
25 95.3 61.0 72.4 63.7 101.0 63.7 76.1 60.0 
26 96.0 63.0 74.0 61.3 99.7 74.0 82.6 66.7 
27 117.7 73.3 88.1 70.3 109.3 66.0 80.4 57.3 
 
SAP, Systolic Arterial Pressure 
DAP, Diastolic Arterial Pressure 
MAP, Mean Arterial Pressure 
HR, Heart Rate 
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Table A.3. Raw data for pain intensity during cold pressor test following normal sleep. 
 
 
Pain Intensity 
Subject Base 
15 
sec 
30 
sec 
45 
sec 
60 
sec 
75 
sec 
90 
sec 
105 
sec 
120 
sec 
1 6 8 9 10 11 12 12 13 13 
2 6 9 12 14 15 15 15 15 15 
3 6 7 11 13 13 14 14 12 11 
4 6 9 11 11 13 14 14 14 14 
5 6 11 13 14 13 12 12 11 12 
6 6 9 10 12 13 14 16 16 17 
7 6 12 13 15 15 14 14 14 14 
8 6 11 13 15 15 16 16 16 17 
9 6 7 9 11 12 14 15 15 14 
10 6 10 10 11 11 10 9 8 7 
11 6 11 13 14.5 15 16 16.5 16 15 
12 6 9 11 13 15 15 15 15 15 
13 6 10 13 15 16 16 15 14 14 
14 6 17 18 18 18 18 18 18 18 
15 6 8 8 9 9 10 11 11 12 
16 6 7 7 9 9 10 10 11 13 
17 6 6 6 6 6 6 6 6 6 
18 6 9 9 10 10 11 11 12 12 
19 6 10 13 14 14 14 14 15 15 
20 6 11 12 13 15 15 16 16 15 
21 6 11 12 14 14 16 17 20 20 
22 6 10 11 15 17 18 17 15 15 
23 6 15 17 17 18 17 18 18 18 
24 6 13 14 17 16 15 14 13 11 
25 6 9 10 11 13 13 13 13 13 
26 6 9 11 15 17 18 19 19 19 
27 6 9 10 11 13 13 12 11 11 
 
sec, seconds 
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Table A.4. Raw data for pain intensity during cold pressor test following 24-hour total sleep deprivation. 
 
 
Pain Intensity 
Subject Base 
15 
sec 
30 
sec 
45 
sec 
60 
sec 
75 
sec 
90 
sec 
105 
sec 
120 
sec 
1 6 9 10 10 11 11 12 12 13 
2 6 13 15 15 15 17 18 18 18 
3 6 7 9 14 15 15 13 12 12 
4 6 8 10 15 15 15 16 16 16 
5 6 13 15 15 16 14 11 11 10 
6 6 9 12 15 15 17 17 18 18 
7 6 12 15 16 18 18 18 17 17 
8 6 9 10 13 13 14 15 17 17 
9 6 6 10 12 15 15 16 16 16 
10 6 15 17 17 17 18 17 15 13 
11 6 14 15 17 18 19 19 19 19 
12 6 9 11 12 12 13 14 14 14 
13 6 15 14 14 14 16 16 16 16 
14 6 17 17 17 17 17 17 17 17 
15 6 9 10 12 15 15 15 16 16 
16 6 7 9 11 13 15 17 17 17 
17 6 7 7.5 7.5 8 8 8 8 8 
18 6 9 9 10 10 10 10 10 11 
19 6 11 12 12 13 13 13 13 13 
20 6 15 16 17 17 18 18 18 18 
21 6 11 13 16 18 20 20 20 20 
22 6 15 16 18 19 16 14 14 16 
23 6 15 18 18 17 16 17 17 16 
24 6 15 15 17 15 15 15 13 13 
25 6 7 10 11 14 15 17 17 18 
26 6 11 13 15 16 18 18 18 18 
27 6 9 10 11 13 14 13 12 12 
 
 
sec, seconds 
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Table A.5 Sleep hours for days preceding normal sleep and TSD testing sessions. 
 
  
 
Normal Sleep 24-Hour Total Sleep Deprivation 
Subject Day 1 Day 2 Day 3 Day 4 Day 1 Day 2 Day 3 Day 4 
1 7.00 8.00 8.00 7.75 7.50 7.00 7.25 0.00 
2 6.50 7.50 7.50 7.00 6.00 7.50 9.00 0.00 
3 7.00 8.00 8.00 6.00 5.00 6.00 7.50 0.00 
4 7.50 8.00 8.50 7.00 9.00 7.00 9.00 0.00 
5 8.50 5.00 8.75 7.25 9.75 5.50 10.25 0.00 
6 9.00 7.00 7.75 6.50 8.50 9.00 7.50 0.00 
7 8.00 8.00 6.50 6.25 4.50 7.75 7.50 0.00 
8 7.25 4.75 7.00 6.75 7.00 6.25 4.50 0.00 
9 6.25 6.75 6.00 6.75 7.00 3.75 6.00 0.00 
10 4.00 4.00 7.00 6.00 9.75 8.00 7.00 0.00 
11 9.75 5.50 7.75 5.50 8.00 9.00 7.00 0.00 
12 8.50 7.00 10.00 8.00 9.00 9.00 7.50 0.00 
13 8.00 8.00 8.00 6.50 6.00 7.00 7.00 0.00 
14 8.00 9.50 8.75 7.00 10.00 9.75 7.75 0.00 
15 7.50 10.00 7.75 6.50 9.00 10.50 7.75 0.00 
16 8.75 9.00 7.45 7.25 7.00 8.75 7.25 0.00 
17 7.00 8.00 8.00 7.00 10.50 7.50 6.50 0.00 
18 6.75 8.00 7.00 6.25 8.75 7.25 4.00 0.00 
19 9.50 8.50 6.50 7.00 7.00 8.50 9.00 0.00 
20 5.50 8.25 5.00 7.00 6.00 7.00 7.00 0.00 
21 7.00 7.75 7.00 7.00 7.00 5.00 7.50 0.00 
22 7.00 7.00 7.50 8.00 7.50 8.00 6.00 0.00 
23 6.00 8.50 7.50 7.50 6.75 9.00 8.75 0.00 
24 7.00 7.25 8.50 6.00 7.75 9.25 7.00 0.00 
25 9.50 8.00 7.50 7.50 7.75 8.00 8.00 0.00 
26 7.50 7.50 8.00 5.00 7.50 8.75 9.25 0.00 
27 7.00 4.50 6.50 4.50 5.25 5.00 7.00 0.00 
 
 
Bolded numbers denote subject self-reported sleep time. 
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Table A.6 Sex hormone levels following Normal sleep and 24-hour total sleep deprivation. 
 
 
Normal Sleep 24-Hour Total Sleep Deprivation 
Subject Estradiol pg/ml Progesterone ng/ml 
Estradiol 
pg/ml Progesterone ng/ml 
1 27 
 
1.97 
 
23 
 
1.10 
 2 16 
 
1.57 
 
24 
 
1.99 
 3 32 
 
2.41 
 
15 
 
1.17 
 4 14 
 
3.17 
 
16 
 
3.10 
 5 37 
 
1.73 
 
24 
 
2.06 
 6 29 
 
3.65 
 
21 
 
2.46 
 7 28 
 
1.87 
 
23 
 
1.13 
 8 19 
 
2.50 
 
16 
 
1.65 
 9 27 
 
2.00 
 
16 
 
1.51 
 10 39 
 
2.32 
 
24 
 
1.88 
 11 19 
 
1.14 
 
22 
 
0.99 
 12 22 
 
2.23 
 
20 
 
1.28 
 13 25 
 
3.19 
 
36 
 
1.66 
 14 30 
 
2.77 
 
25 
 
1.83 
 15 21 
 
2.05 
 
20 
 
2.28 
 16 41 
 
1.38 
 
37 
 
0.42 
 17 20 
 
1.86 
 
16 
 
1.03 
 18 27 
 
2.12 
 
23 
 
1.36 
 19 24 
 
1.40 
 
30 
 
0.91 
 20 20 
 
2.12 
 
21 
 
0.79 
 21 12 
 
1.75 
 
23 
 
1.45 
 22 23 
 
1.83 
 
19 
 
1.93 
 23 21 
 
1.62 
 
25 
 
1.74 
 24 52 
 
1.29 
 
42 
 
1.46 
 25 32 
 
2.18 
 
36 
 
1.63 
 26 130 
 
3.25 
 
47 
 
2.31 
 27 - 
 
- 
 
- 
 
- 
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Appendix B: Summary of Statistics for Study 1  
Mean data for Pain Intensity  
 
Table B.1 Mean data for ∆Pain Intensity during CPT 
 
Variable Condition N Mean Std. Error Mean 
∆Pain Intensity 
15s 
NS 
TSD 
27 
27 
3.89 
5.00 
0.46 
0.63 
∆Pain Intensity 
30s 
NS 
TSD 
27 
27 
5.33 
6.54 
0.52 
0.58 
∆Pain Intensity 
45s 
NS 
TSD 
27 
27 
6.87 
7.98 
0.54 
0.54 
∆Pain Intensity 
60s 
NS 
TSD 
27 
27 
7.56 
8.78 
0.56 
0.50 
∆Pain Intensity 
75s 
NS 
TSD 
27 
27 
7.93 
9.26 
0.54 
0.52 
∆Pain Intensity 
90s 
NS 
TSD 
27 
27 
8.06 
9.33 
0.58 
0.55 
∆Pain Intensity 
105s 
NS 
TSD 
27 
27 
7.96 
9.22 
0.61 
0.57 
∆Pain Intensity 
120s 
NS 
TSD 
27 
27 
7.93 
9.26 
0.62 
0.57 
 
Table B.2 ∆Mean & Peak Pain Intensity during CPT 
 
Variable Condition N Mean Std. Error Mean 
∆Mean Pain Intensity NS 
TSD 
27 
27 
6.95 
8.18 
0.50 
0.47 
∆Peak Pain Intensity NS 
TSD 
27 
27 
8.91 
10.22 
0.56 
0.51 
 
 
 
Table B.3 ∆Mean Pain Intensity during CPT by sex 
 
Variable Condition Sex N Mean Std. Error Mean 
∆Mean Pain 
Intensity 
NS 
 
M 
F 
14 
13 
7.16 
6.72 
0.55 
0.87 
∆Mean Pain 
Intensity 
TSD M 
F 
14 
13 
8.70 
7.62 
0.48 
0.82 
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Repeated Measures ANOVA 
 
Repeated measures ANOVA for baseline Weight (kg). Condition (NS vs. TSD) as within-subjects factor 
and sex (male vs. female) as between-subjects factor. 
 
Mauchley's Test of Sphericity 
Within Subjects 
Effect 
Mauchly's W Approx. Chi-
Square 
df Sig Huynh-
Feldt 
Condition 1.000 0.000 0 . 1.000 
 
Test of Within-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (2-tailed) 
Condition 0.277 1.000 0.227 0.519 0.478 
Condition × Sex 0.997 1.000 0.997 1.867 0.184 
 
Test of Between-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (2-tailed) 
Sex 3317.238 1 3317.238 8.921 0.006 
 
 
Repeated measures ANOVA for baseline SAP (mmHg). Condition (NS vs. TSD) as within-subjects factor 
and sex (male vs. female) as between-subjects factor. 
 
Mauchley's Test of Sphericity 
Within Subjects 
Effect 
Mauchly's W Approx. Chi-
Square 
df Sig Huynh-Feldt 
Condition 1.000 0.000 0 . 1.000 
 
Test of Within-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Condition 178.446 1.000 178.446 9.725 0.003 
Condition × Sex 75.667 1.000 75.657 4.123 0.027 
 
Test of Between-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Sex 2780.500 1 2780.500 34.540 0.000 
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Repeated measures ANOVA for baseline DAP (mmHg). Condition (NS vs. TSD) as within-subjects factor 
and sex (male vs. female) as between-subjects factor. 
 
Mauchley's Test of Sphericity 
Within Subjects 
Effect 
Mauchly's W Approx. Chi-
Square 
df Sig Huynh-
Feldt 
Condition 1.000 0.000 0 . 1.000 
 
Test of Within-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Condition 106.672 1.000 106.672 12.250 0.001 
Condition × Sex 1.639 1.000 1.639 0.188 0.334 
 
Test of Between-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Sex 47.285 1 47.285 0.862 0.181 
 
 
Repeated measures ANOVA for baseline MAP (mmHg). Condition (NS vs. TSD) as within-subjects factor 
and sex (male vs. female) as between-subjects factor. 
 
 
Mauchley's Test of Sphericity 
Within Subjects 
Effect 
Mauchly's W Approx. Chi-
Square 
df Sig Huynh-
Feldt 
Condition 1.000 0.000 0 . 1.000 
 
 
Test of Within-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Condition 127.841 1.000 127.841 16.313 0.000 
Condition × Sex 4.172 1.000 4.172 0.532 0.236 
 
 
Test of Between-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Sex 490.547 1 490.547 12.545 0.001 
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Repeated measures ANOVA for baseline Estradiol.  Condition is within-subjects factor, sex is the between 
subjects-factor. 
 
Mauchley's Test of Sphericity 
Within Subjects 
Effect 
Mauchly's W Approx. Chi-
Square 
df Sig Huynh-
Feldt 
Condition 1.000 0.000 0 . 1.000 
 
Test of Within-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Condition 403.718 1.000 403.718 2.561 0.062 
Condition × 
Sex 
17.411 1.000 17.411 0.110 0.372 
 
Test of Between-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Sex 1485.165 1 1485.165 4.054 0.028 
 
Repeated measures ANOVA for baseline Progesterone.  Condition is within-subjects factor, sex is the 
between subjects-factor. 
 
 
Mauchley's Test of Sphericity 
Within Subjects 
Effect 
Mauchly's W Approx. Chi-
Square 
df Sig Huynh-
Feldt 
Condition 1.000 0.000 0 . 1.000 
 
Test of Within-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Condition 4.118 1.000 4.118 30.640 0.000 
Condition × Sex 0.587 1.000 0.587 4.364 0.024 
 
Test of Between-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Sex 0.845 1 0.845 1.409 0.124 
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Repeated measures ANOVA for ∆Pain Intensity during CPT.  Condition and Time are within-subjects 
factors, sex is the between subjects-factor. 
 
 
Mauchley's Test of Sphericity 
Within Subjects 
Effect 
Mauchly's W Approx. Chi-
Square 
df Sig Huynh-
Feldt 
Condition 1.000 0.000 0 . 1.000 
 
Test of Within-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-
tailed) 
Condition 155.983 1.000 155.983 13.481 0.000 
Condition × Sex 5.778 1.000 5.778 0.499 0.244 
Time 3519.263 2.534 1388.564 93.908 0.000 
Time × Sex 25.205 2.534 9.945 0.673 0.274 
Condition × 
Time  
20.699 3.737 5.538 2.245 0.038 
Cond × Time × 
Sex 
6.346 3.737 1.698 0.688 0.296 
 
Test of Between-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Sex 51.385 1 51.385 0.626 0.219 
 
 
Repeated measures ANOVA for ∆Peak Pain Intensity during CPT.  Condition is within-subjects factor, 
sex is the between subjects-factor. 
 
 
Mauchley's Test of Sphericity 
Within Subjects 
Effect 
Mauchly's W Approx. Chi-
Square 
df Sig Huynh-
Feldt 
Condition 1.000 0.000 0 . 1.000 
 
 
Test of Within-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Condition 22.524 1.000 22.524 10.949 0.002 
Condition × Sex 4.858 1.000 4.858 2.361 0.069 
 
 
Test of Between-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Sex 13.892 1 13.892 1.044 0.159 
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Repeated measures ANOVA for ∆Average Pain Intensity during CPT.  Condition is within-subjects 
factor, sex is the between subjects-factor. 
 
 
Mauchley's Test of Sphericity 
Within Subjects 
Effect 
Mauchly's W Approx. Chi-
Square 
df Sig Huynh-
Feldt 
Condition 1.000 0.000 0 . 1.000 
 
 
Test of Within-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Condition 19.995 1.000 19.995 12.131 0.001 
Condition × Sex 1.362 1.000 1.362 0.826 0.186 
 
 
Test of Between-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (1-tailed) 
Sex 7.768 1 7.768 0.702 0.205 
 
 
 
 
 
Post-hoc Paired T-Tests 
 
Men baseline SAP (mmHg) 
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (1-
tailed) Pairing Mean Lower Upper t df 
NS vs. TSD -6.01 -9.59 -2.43 -3.62 13 0.002 
 
Women baseline SAP (mmHg) 
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (1-
tailed) Pairing Mean Lower Upper t df 
NS vs. TSD -1.27 -4.83 2.29 -0.776 12 0.227 
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Men baseline Progesterone  
 
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (1-
tailed) Pairing Mean Lower Upper t df 
NS vs. TSD 0.351 0.022 0.680 2.308 13 0.019 
 
 
Women baseline Progesterone  
 
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (1-
tailed) Pairing Mean Lower Upper t df 
NS vs. TSD 0.778 0.491 1.06 5.983 11 0.000 
 
 
 
 
 
∆Pain Intensity during CPT 
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (1-
tailed) Pairing Mean Lower Upper t df 
NS 15s vs. TSD 15s -1.11 -1.92 -0.03 -2.82 26 0.005 
NS 30s vs. TSD 30s  -1.20 -2.03 -0.04 -3.01 26 0.003 
NS 45s vs. TSD 45s -1.11 -1.87 -0.35 -3.02 26 0.003 
NS 60s vs. TSD 60s -1.22 -2.16 -0.28 -2.67 26 0.007 
NS 75s vs. TSD 75s -1.33 -2.32 -0.35 -2.78 26 0.005 
NS 90s vs. TSD 90s -1.28 -2.31 -0.25 -2.55 26 0.009 
NS 105s vs. TSD 
105s 
-1.26 -2.20 -0.32 -2.75 26 0.006 
NS 120s vs. TSD 
120s 
-1.33 -2.21 -0.46 -3.12 26 0.002 
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Appendix C: Raw data for Study 2 
 
Table C.1. Anthropometric data 
 
  
Early Follicular Mid-Luteal 
Subject 
Age 
(yrs) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kg/m2) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kg/m2) 
1 19 164.5 65.5 24.21 163.5 65.5 24.50 
2 21 163.5 53.0 19.83 164.0 52.0 19.33 
3 19 177.5 70.0 22.22 179.0 70.0 21.85 
4 20 164.0 73.5 27.33 162.0 72.0 27.43 
5 21 167.0 79.0 28.33 166.5 76.5 27.60 
6 18 159.0 97.0 38.37 159.0 99.0 39.16 
7 30 168.0 95.0 33.66 170.0 94.5 32.70 
8 23 168.0 57.5 20.37 168.0 58.0 20.55 
9 19 165.5 56.0 20.45 166.0 57.0 20.69 
10 21 164.0 62.0 23.05 164.0 61.0 22.68 
 
BMI, Body Mass Index 
 
 
Table C.2. Raw data for seated resting blood pressure (mmHg) and heart rate (beats/min). 
 
 
Early Follicular Mid-Luteal 
Subject SAP DAP MAP HR SAP DAP MAP HR 
1 102.7 70.3 81.1 53.3 103.7 70.0 81.2 53.0 
2 97.3 70.7 79.6 53.3 97.3 66.7 76.9 53.7 
3 110.7 61.0 77.6 50.7 114.7 53.7 74.0 61.3 
4 83.0 79.3 80.5 68.0 94.3 54.3 67.6 70.7 
5 104.4 70.0 81.5 68.7 103.0 68.0 79.7 65.3 
6 103.0 63.3 76.5 70.0 98.3 68.7 78.6 65.3 
7 144.7 101.3 115.8 78.7 149.0 96.7 114.1 73.0 
8 96.7 55.3 69.1 56.7 102.3 53.0 69.4 62.3 
9 93.0 57.3 69.2 63.7 102.3 56.3 71.6 59.0 
10 119.0 65.7 83.5 56.0 101.0 58.0 72.3 55.7 
 
 
SAP, Systolic Arterial Pressure 
DAP, Diastolic Arterial Pressure 
MAP, Mean Arterial Pressure 
HR, Heart Rate 
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Table C.3. Raw data for pain intensity during cold pressor test during Early Follicular Phase. 
 
 
Pain Intensity Early Follicular 
Subject Base 
15 
sec 
30 
sec 
45 
sec 
60 
sec 
75 
sec 
90 
sec 
105 
sec 
120 
sec 
1 6 15.0 15.0 16.0 17.0 17.0 15.0 15.0 14.0 
2 6 7.0 9.0 10.0 11.0 13.0 14.0 15.0 16.0 
3 6 9.0 13.0 17.0 17.0 18.0 15.0 15.0 17.0 
4 6 8.0 11.0 14.0 17.0 19.0 19.0 20.0 20.0 
5 6 16.0 18.0 19.0 19.0 19.0 17.0 16.0 15.0 
6 6 8.0 8.0 10.0 8.0 8.0 8.0 8.0 8.0 
7 6 18.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 
8 6 15.0 16.0 17.0 16.0 16.0 16.0 17.0 16.0 
9 6 9.0 11.0 12.0 12.0 14.0 13.0 13.0 13.0 
10 6 12.0 12.0 14.0 15.0 16.0 16.0 17.0 18.0 
 
 
Table C.4. Raw data for pain intensity during cold pressor test during Mid-Luteal Phase. 
 
 
Pain Intensity Mid-Luteal 
Subject Base 
15 
sec 
30 
sec 
45 
sec 
60 
sec 
75 
sec 
90 
sec 
105 
sec 
120 
sec 
1 6 17.0 18.0 18.0 17.0 16.0 16.0 15.0 15.0 
2 6 7.0 9.0 10.0 12.0 13.0 15.0 16.0 16.0 
3 6 7.0 8.0 18.0 18.0 16.0 16.0 14.0 12.0 
4 6 11.0 14.0 16.0 18.0 19.0 19.5 19.0 19.0 
5 6 16.0 15.0 15.0 17.0 15.0 14.0 12.0 10.0 
6 6 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0 
7 6 11.0 18.0 20.0 20.0 20.0 18.0 18.0 18.0 
8 6 16.0 15.0 15.0 15.0 16.0 15.0 15.0 16.0 
9 6 9.0 10.0 10.0 12.0 13.0 13.0 12.0 13.0 
10 6 10.0 10.0 13.0 14.0 15.0 16.0 16.0 17.0 
 
sec, seconds 
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Table C.5 Sleep hours for day preceding Early Follicular and Mid-Luteal testing sessions. 
 
 
Early Follicular Mid-Luteal 
Subject Day 1 Day 2 Day 3 Day 4 Day 1 Day 2 Day 3 Day 4 
1 6.00 7.00 7.25 0.00 9.00 7.00 5.45 0.00 
2 7.00 5.00 6.00 0.00 6.25 8.75 6.25 0.00 
3 8.50 6.75 8.00 0.00 6.50 8.75 4.25 0.00 
4 7.75 8.25 7.25 0.00 7.00 8.00 8.25 0.00 
5 8.00 9.25 6.25 0.00 8.25 6.00 5.50 0.00 
6 6.00 8.50 5.00 0.00 9.50 6.50 5.75 0.00 
7 9.25 6.75 4.00 0.00 8.50 7.50 7.00 0.00 
8 10.50 9.00 8.25 0.00 6.50 7.00 7.00 0.00 
9 6.50 7.50 5.50 0.00 6.75 7.25 6.50 0.00 
10 7.75 8.75 8.50 0.00 7.25 8.00 9.50 0.00 
 
Bold numbers denote subject reported sleep hours 
 
Table C.6 Sex hormone levels during Early Follicular and Mid-Luteal Phases. 
 
 
Early Follicular Mid-Luteal 
Subject 
Estradiol 
pg/ml Progesterone ng/ml 
Estradiol 
pg/ml Progesterone ng/ml 
1 25 
 
3.14 
 
28 
 
3.02 
 2 19 
 
1.22 
 
120 
 
6.81 
 3 15 
 
1.06 
 
31 
 
1.74 
 4 29 
 
1.54 
 
81 
 
7.20 
 5 26 
 
1.22 
 
44 
 
1.11 
 6 32 
 
1.00 
 
32 
 
0.79 
 7 22 
 
0.78 
 
89 
 
8.06 
 8 42 
 
1.82 
 
60 
 
3.27 
 9 33 
 
1.30 
 
87 
 
10.20 
 10 43 
 
1.60 
 
85 
 
7.21 
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Appendix D: Summary of Statistics for Study 2 
 
Mean Data for Pain Intensity 
 
Table D.1 ∆Pain Intensity during CPT 
 
Variable Condition N Mean Std. Error Mean 
∆Pain Intensity 
15s 
EF 
ML 
10 
10 
5.7 
5.2 
1.27 
1.21 
∆Pain Intensity 
30s 
EF 
ML 
10 
10 
7.3 
6.5 
1.23 
1.25 
∆Pain Intensity 
45s 
EF 
ML 
10 
10 
8.9 
8.3 
1.11 
1.26 
∆Pain Intensity 
60s 
EF 
ML 
10 
10 
9.2 
9.1 
1.19 
1.15 
∆Pain Intensity 
75s 
EF 
ML 
10 
10 
10.0 
9.1 
1.14 
1.06 
∆Pain Intensity 
90s 
EF 
ML 
10 
10 
9.3 
9.1 
1.05 
0.98 
∆Pain Intensity 
105s 
EF 
ML 
10 
10 
9.6 
8.5 
1.10 
1.01 
∆Pain Intensity 
120s 
EF 
ML 
10 
10 
9.7 
8.4 
1.13 
1.13 
 
 
Table D.2 ∆Mean & Peak Pain Intensity during CPT 
 
Variable Condition N Mean Std. Error Mean 
∆Mean Pain Intensity EF 
ML 
10 
10 
8.72 
8.03 
1.02 
0.93 
∆Peak Pain Intensity EF 
ML 
10 
10 
10.9 
10.3 
0.96 
1.11 
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Repeated Measures ANOVA 
 
Repeated measures ANOVA for ∆Pain Intensity during CPT.  Condition and Time are within-subjects 
factors. 
 
 
Mauchley's Test of Sphericity 
Within Subjects 
Effect 
Mauchly's W Approx. Chi-
Square 
df Sig Huynh-
Feldt 
Condition 1.000 0.000 0 . 1.000 
 
Test of Within-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (2-tailed) 
Condition 17.112 1.000 17.112 2.884 0.124 
Time 1530.428 3.485 439.195 23.142 0.000 
Condition × Time  8.050 5.213 1.544 0.972 0.447 
 
 
Repeated measures ANOVA for ∆Peak Pain Intensity during CPT. Condition is within-subjects factor. 
 
 
Mauchley's Test of Sphericity 
Within Subjects 
Effect 
Mauchly's W Approx. Chi-
Square 
df Sig Huynh-
Feldt 
Condition 1.000 0.000 0 . 1.000 
 
 
Test of Within-Subjects Effects 
Source Type III Sum of 
Squares 
df Mean Square F Sig. (2-tailed) 
Condition 2.113 1.000 2.113 4.738 0.057 
 
 
Repeated measures ANOVA for ∆ Average Intensity during CPT.  Condition is within-subjects factor. 
 
 
Mauchley's Test of Sphericity 
Within Subjects 
Effect 
Mauchly's W Approx. Chi-
Square 
df Sig Huynh-
Feldt 
Condition 1.000 0.000 0 . 1.000 
 
 
Test of Within-Subjects Effects 
Source 
Type III Sum of 
Squares 
df Mean Square F Sig. (2-tailed) 
Condition 2.380 1.000 2.380 2.890 0.123 
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Paired T-Tests for Baseline Variables 
 
Paired t-test for Baseline Weight  
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (2-
tailed) Pairing Mean Lower Upper t df 
EF vs. ML 0.3000 -0.627 1.227 0.732 9 0.483 
 
Paired t-test for Baseline BMI  
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (2-
tailed) Pairing Mean Lower Upper t df 
EF vs. ML 0.133 -0.252 0.518 0.781 9 0.455 
Paired t-test for Baseline SAP 
 
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (2-
tailed) Pairing Mean Lower Upper t df 
EF vs. ML -1.14 -7.06 4.78 -0.436 9 0.673 
 
Paired t-test for Baseline DAP 
 
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (2-
tailed) Pairing Mean Lower Upper t df 
EF vs. ML 4.88 -0.843 10.61 1.929 9 0.086 
 
Paired t-test for Baseline MAP 
 
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (2-
tailed) Pairing Mean Lower Upper t df 
EF vs. ML 2.90 -0.828 6.628 1.760 9 0.112 
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Paired t-test for Baseline HR 
 
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (2-
tailed) Pairing Mean Lower Upper t df 
EF vs. ML -0.020 -3.71 3.67 -0.012 9 0.990 
 
 
 
Paired t-test for Baseline Estradiol 
 
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (1-
tailed) Pairing Mean Lower Upper t df 
EF vs. ML -37.10 -60.00 -14.20 -3.67 9 0.003 
 
 
Paired t-test for Baseline Progesterone 
 
Paired Samples Test 
 Paired Differences  
  95% Confidence Interval   Sig. (1-
tailed) Pairing Mean Lower Upper t df 
EF vs. ML -3.47 -5.96 -0.984 -3.16 9 0.006 
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Appendix E: Modified Borg Scale 
Modified Borg Rating of Perceived Pain 
 
6 
Very Low Pain 7 
8 
Low Pain 9 
10 
Fairly Painful 11 
12 
Somewhat Painful 13 
14 
Painful 15 
16 
Very Painful 17 
18 
Almost Unbearable 19 
20 
 
